Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

Van der Hulle, T.; den Exter, P. L.; Planquette, B.; Meyer, G.; Soler, S.; Monreal, M.; Jiménez, D.; Portillo, A. K.; O'Connell, C.; Liebman, H. A.; Shteinberg, M.; Adir, Y.; Tiseo, M.; Bersanelli, M.; Abdel-Razeq, H. N.; Mansour, A. H.; Donnelly, O. G.; Radhakrishna, G.; Ramasamy, S.; Bozas, G.; Maraveyas, A.; Shinagare, A. B.; Hatabu, H.; Nishino, M.; Huisman, M. V.; Klok, F. A.

doi:10.1111/jth.13172

All Outputs (7)

Characterisation of duramycin as an anti-cancer agent (2016)
Thesis
Broughton, L. J. (2016). Characterisation of duramycin as an anti-cancer agent. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4219417

Duramycin is a relatively small (~2kDa) tetracyclic peptide that has a defined three-dimensional (3D) structure, this structure forms a stable binding pocket which specifically recognises the plasma membrane phospholipid phosphatidylethanolamine (PE)... Read More about Characterisation of duramycin as an anti-cancer agent.

Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy (2016)
Journal Article
Broughton, L. J., Giuntini, F., Savoie, H., Bryden, F., Boyle, R. W., Maraveyas, A., & Madden, L. A. (2016). Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy. Journal of photochemistry and photobiology. B, Biology, 163, 374-384. https://doi.org/10.1016/j.jphotobiol.2016.09.001

Duramycin, through binding with phosphatidylethanolamine (PE), has been shown to be a selective molecular probe for the targeting and imaging of cancer cells. Photodynamic therapy aims to bring about specific cytotoxic damage to tumours through deliv... Read More about Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy.

Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release (2016)
Journal Article
Ettelaie, C., Collier, M. E., Featherby, S., Greenman, J., & Maraveyas, A. (2016). Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release. BBA - Molecular Cell Research, 1863(11), 2846-2857. https://doi.org/10.1016/j.bbamcr.2016.09.005

Restriction of tissue factor (TF) activity at the cell surface and TF release are critical for prevention of excessive coagulation. This study examined the regulation of TF dephosphorylation and its release through ubiquitination. A plasmid containin... Read More about Oligoubiquitination of tissue factor on Lys255 promotes Ser253-dephosphorylation and terminates TF release.

Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles (2016)
Journal Article
Gardiner, E., Madden, L., Maraveyas, A., Adesanya, M. A., Hall, J., & Sayala, H. (2016). Chemotherapy treatment of multiple myeloma patients increases circulating levels of endothelial microvesicles. Thrombosis Research, 146, 20-22. https://doi.org/10.1016/j.thromres.2016.08.017

Correspondence

Duramycin-induced calcium release in cancer cells (2016)
Journal Article
Broughton, L. J., Crow, C., Madden, L. A., & Maraveyas, A. (2016). Duramycin-induced calcium release in cancer cells. Anti-cancer drugs, 27(3), 173-182. https://doi.org/10.1097/cad.0000000000000313

Introduction: Duramycin through binding with phosphatidylethanolamine (PE) has shown potential to be an effective anti-tumour agent. However its mode of action in relation to tumour cells is not fully understood. Methods: PE expression on the surface... Read More about Duramycin-induced calcium release in cancer cells.

Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression (2016)
Journal Article
Ettelaie, C., Collier, M. E. W., Featherby, S., Benelhaj, N. E., Greenman, J., & Maraveyas, A. (2016). Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression. Thrombosis journal, 14(2), Article ARTN 2. https://doi.org/10.1186/s12959-016-0075-3

Background Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear. Methods In this study the upregulation of TF re... Read More about Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: correlation with tissue factor and PAR2 expression.

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients (2016)
Journal Article
Van der Hulle, T., den Exter, P. L., Planquette, B., Meyer, G., Soler, S., Monreal, M., …Klok, F. A. (2016). Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. Journal of thrombosis and haemostasis : JTH, 14(1), 105-113. https://doi.org/10.1111/jth.13172

Essentials: We performed a pooled analysis of 926 patients with cancer-associated incidental pulmonary embolism (IPE). Vitamin K antagonists (VKA) are associated with a higher risk of major hemorrhage. Recurrence risk is comparable after subsegmental... Read More about Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.